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Protection of pigs against challenge with
virulent Streptococcus suis serotype 2 strains
by a muramidase-released protein and
extracellular factor vaccine
H. J. WISSELINK, U. VECHT, N. STOCKHOFE-ZURWIEDEN, H. E. SMITH
The efficacy of a muramidase-released protein (MRP) and extracellular factor (EF) vaccine in preventing
infection and disease in pigs challenged either with a homologous or a heterologous Streptococcus suis
serotype 2 strain (MRP+EF+) was compared with the efficacy of a vaccine containing formalin-killed bacterin
of S suis serotype 2 (MRP+EF+). The enhancement of the immune response by different adjuvants (a water-in-
oil emulsion [wo] and an aluminium hydroxide-based adjuvant [AHJ) and their side effects were also studied.
The MRP and EF were purified by affinity chromatography. Pigs were vaccinated twice at three weeks and six
weeks of age and challenged intravenously with virulent S suis serotype 2 strains (MRP+EF+) at eight weeks
of age. At challenge, the pigs vaccinated with MRP+EF/WO had high anti-MRP and anti-EF titres and were
protected as effectively as pigs vaccinated with wo-formulated vaccines with bacterin. Eight of the nine pigs
survived the challenge and almost no clinical signs of disease were observed. The titres obtained with the
MRP+EF/AH vaccine were low and only two of the five pigs were protected. Pigs vaccinated with either MRP or
EF were less well protected; three of the four pigs died after challenge but the clinical signs of disease were
significantly less severe than those observed in the placebo-vaccinated pigs. The protective capacity of the
bacterin/AH vaccine was very low, and the mortality among these pigs was as high as in the placebo-
vaccinated pigs (80 per cent). Postmortem histological examination revealed meningitis, polyserositis and
arthritis in the clinically affected pigs. The results demonstrate that a subunit vaccine containing both MRP
and EF, formulated with the wo adjuvant, protected pigs against challenge with virulent S suis type 2 strains.
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STREPTOCOCCAL meningitis, polyserositis and polyarthri-
tis, is a severe, often fatal disease ofyoung pigs at weaning, and
is usually caused by Streptococcus suis serotype 2 (Vecht and
others 1985, Higgins and others 1992, Reams and others
1994). S suis strains can be differentiated by serotype on the
basis of their capsular polysaccharides. At present, 35
serotypes are known (Perch and others 1983, Gottschalk and
others 1989, 1991, Higgins and others 1995). The virulence of
most serotypes is unclear. Strains ofserotypes 2 and 1 are con-
sidered to be the most virulent serotypes, but strains of some
other serotypes, such as 7, 9 and 14 have also been associated
with disease (Sihovenen and others 1988, Jacobs and others
1995, MacLennan and others 1996).
The economic impact of S suis infections on the pig indus-
try is substantial (Chengappa and others 1990), and the
prophylactic use of antibiotics in food and drinking water
has so far been unsuccessful in controlling the disease.
Furthermore, antibiotics are becoming less effective because
of an increase in resistance among S suis isolates and their use
is unpopular because of the public awareness of antimicro-
bial residues (Aarestrup and others 1998).
Little is known about the protective antigens of S suis.
Whole-cell vaccines with live avirulent or killed virulent S suis
serotype 2 cells protected pigs against challenge with a strain
of a homologous serotype (Holt and others 1988, 1990,
Busque and others 1997). However, vaccination with whole
cells did not induce protection against challenge with a strain
of a heterologous serotype (Kebede and others 1990). Jacobs
and others (1996) showed that a vaccine based on the puri-
fied 54 kDa suilysin protected against a homologous chal-
lenge, but the absence of this haemolysin from a substantial
number of isolates obtained from diseased pigs limits the
usefulness of this vaccine (Segers and others 1998).
In previous work, the authors identified two proteins, the
136 kDa muramidase-released protein (MRP) and the 110 kDa
extracellular factor protein (EF), as markers of virulent S suis
serotype 1 and 2 strains (Vecht and others 1991). The MRP iS
a membrane-associated protein and EF is an extracellular pro-
tein. Both are transported across the bacterial membrane and
are major antigens recognised by convalescent sera of infected
pigs (Vecht and others 1991).
This paper describes the results of studies of the efficacy
of MRP and EF vaccines in preventing infection and disease in
pigs challenged with a homologous or a heterologous S suis
serotype 2 strain (MRP+EF+), in comparison with the protec-
tive capacity of a vaccine containing formalin-killed bacterin
of S suis serotype 2 (MRP+EF+).
MATERIALS AND METHODS
Bacterial strains
Strains 4005 (3) and 3881 (10) ofSsuis serotype 2, both belong-
ing to the phenotype MRP+EF+, were used. Both strains were field
isolates, isolated from pigs suffering from meningitis and were
virulent for newborn germ-free pigs (Vecht and others 1992).
Adjuvants
Two adjuvants, a water-in-oil emulsion (Specol; ID-Lelystad)
(wo) and a 2 per cent aluminium hydroxide gel (Alhydrogel;
Superfos Bisosector) (AH) were used.
Antigens
For the preparation of the vaccine, MRP and EF were purified
by affinity chromatography. A two litre culture of strain 4005,
grown in Todd Hewitt broth (CM 189; Oxoid) was centrifuged
at 4000 g for 15 minutes. The supernatant was cleared from
remaining cells by filtration under air pressure through 0-2
pm filters (Millipore). Monoclonal antibodies MRP3, or EF2
(ID-Lelystad) were coupled separately to cyanogen bromide-
activated Sepharose 4B in accordance with the instructions of
the supplier (Pharmacia). After appropriate washing the
bound proteins were eluted with glycine-hydrochloric acid
buffer (0-IM, pH 2.8), and the pH of the fractions was
immediately increased to 7-0 with 1M sodium hydroxide. The
fractions were measured with the MRP or EF double antibody
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sandwich (DAS) ELISA for the detection of MRP and EF proteins
as described byVecht and others (1993). Fractions positive for
MRP and EF were pooled and dialysed overnight against phys-
iological saline. The purified proteins gave single bands in sil-
ver-stained sodium dodecyl sulphate-polyacrylamide gels.
The quantities of proteins were measured with the bicin-
choninic acid protein assay reagent (Pierce), using bovine
serum albumin (BSA) as standard. Approximately 100 [ig of
MRP and 240 jIg of EF were obtained per litre of culture.
For the preparation of the whole-cell vaccine, strain 4005
was incubated overnight at 37°C in 100 ml Todd-Hewitt
broth. The culture contained about 1 x 109 colony-forming
units (cfu)/ml. Fifty ml was centrifuged at 4000 g for 15 min-
utes. Pellets were washed twice in phosphate-buffered saline
(PBS: 136-89 mM sodium chloride, 2-68 mM potassium chlo-
ride, 8-1 mM sodium hydrogen phosphate, 2-79 mM potas-
sium hydrogen phosphate, pH 7-2) and resuspended in 2-5 ml
PBS. To this suspension, 250 V113 per cent formalin was added,
and it was maintained at 4°C overnight. The next day, the
suspension was checked for the absence of live bacteria by
plating on 6 per cent Columbia horse blood agar base (cM
331; Oxoid). To remove formalin, the cells were washed twice
with physiological saline and resuspended in physiological
saline to a final count of approximately 1 x 109 cells/ml.
Vaccine preparation
wo or AH was used as the adjuvant. For the preparation of
emulsions in the wo adjuvant, four parts of the water phase
containing the antigen were mixed with five parts of wo
(Bokhout and others 1981).
For the vaccinations with the AH adjuvant, 1 25 mg metal-
lic aluminium was used per dose, according to the manufac-
turer's instructions. The antigens and AH were stirred for four
hours at 4°C. To control adsorption, 1 ml of the mixture was
centrifuged in an Eppendorf centrifuge at 10,000 rpm for
three minutes, and the supernatants were analysed for the
absence of the antigens either by MRP and EF DAS ELISA (Vecht
and others 1993) or spectrophotometrically by using an
Ultrospec 3000 spectrophotometer (Pharmacia Biotech) at
wavelengths of 250 to 650 nm.
For the preparation of the placebo-vaccines the antigen
solutions were replaced by a physiological saline solution.
Vaccination
Fifty-five three-week-old pigs, crossbreeds of Yorkshire and
Dutch landrace, were obtained from the specified pathogen-
free herd of the ID-Lelystad for two experiments. In both
experiments the pigs were alloted to six treatment groups each
consisting of four or five pigs. The pigs were separated and
housed in boxes at the animal facilities of the ID-Lelystad.
Priming vaccinations were given at the age of three weeks.
Each dose contained 50 jtg MRP, 50 jig EF or 1 x 109 formalin-
killed whole cells, either separately or in combination, and
they were administered intramuscularly, divided over two
injection sites, in both upper hind legs. Three weeks later the
pigs were boosted intramuscularly in the neck with the same
dose of the vaccines without adjuvants.
Challenge
Two weeks after the second vaccination, the pigs were chal-
lenged intravenously in the ear vein with 1 x 107 cfu of the
homologous S suis serotype 2 strain 4005 (experiment 1) or
the heterologous S suis serotype 2 strain 3881 (experiment 2).
The inocula were prepared as described by Vecht and others
(1992). The pigs were monitored twice daily for the following
clinical signs of disease: fever, disorders of the nervous sys-
tem, lameness, inappetence and depression. Blood samples
were taken once a week before the challenge and three times
a week after the challenge to monitor the immune response.
White blood cells were counted with a semi-cell blood
counter (Sysmex, model F 800; Charles Goffin Medical
Systems). The number of neutrophils was calculated after a
differential count of Giemsa-stained blood smears. For ani-
mal welfare reasons, pigs that were moribund or showed ner-
vous signs were killed by an intravenous injection of
pentobarbiturate, exsanguinated and examined postmortem.
Tissue specimens taken from the central nervous system
(CNS), serosae, and joints were examined bacteriologically and
histologically as described byVecht and others (1992). Lesions
resulting from the injections of the vaccines were recorded.
The experiments were approved by the ethical committee
of the Institute for Animal Science and Health in accordance
with Dutch law on animal experiments.
Antibodies against MRP and EF
The sera were tested for antibodies against MRP and EF by an
indirect ELISA. Each well of the polystyrene microtitre plates
was coated for 18 hours at 37°C with 30 ng of MRP for the
indirect MRP ELISA or with 25 ng of EF for the indirect EF ELISA.
Pig sera in two-fold dilutions from 1:5 to 1:5120 in PBS con-
taining 0.05 per cent Tween 80 were added and the plates were
incubated for one hour at 37°C. Serum from a gnotobiotic pig
which had survived an infection with the virulent S suis
serotype 2 strain 4005 (MRP+EF+) was used as a positive con-
trol. As a conjugate, monoclonal antibody mouse anti-swine
immunoglobulin G labelled with horseradish peroxidase (ID-
Lelystad) was used. After incubation for one hour at 37°C, the
substrate 5-aminosalycylic acid with hydrogen peroxide was
added. After incubation for two hours at room temperature,
the absorbance at 450 nm was read. Titres were expressed as
the reciprocal of the log2 of the highest dilution showing an
absorbance of more than 50 per cent of the positive control.
Statistical analysis
Data concerning the mortality and lesions of the various groups
were analysed simultaneously by the non-parametric Fisher-
Freeman-Halton exact test.When there was overall significance,
Fisher's exact test was used to make pair-wise comparisons
between the various groups. In a similar manner, the antibody
titres against MRP and EF, the clinical signs of disease, fever and
the number of leucocytes were subjected to exact median tests
for simultaneous comparisons, followed by exact pair-wise per-
mutation tests. The last test was only used if there was overall
significance. The significance level was set at 95 per cent.
RESULTS
Antibody titres against MRP and EF
All the pigs vaccinated with the MRP and EF vaccines with wo
as adjuvant developed high anti-MRP and anti-EF titres (Table
1). At the time of challenge the average antibody titres against
MRP ranged from 6208 to 23,170 and against EF from 7131 to
13,308. The titres obtained after vaccination with MRP+EF/AH
were much lower; at the time of challenge, the average
antibody titre against MRP was 388 and against EF it was 1522.
Pigs vaccinated with the bacterin vaccines developed low
anti-MRP titres only. In the pigs vaccinated with bacterin/wo
they started to develop after the booster administration to an
average anti-MRP titre of 158 at the time of challenge. No anti-
EF titres could be detected in this group either before or after
challenge. In the bacterin/AH group, none of the pigs had
anti-MRP or anti-EF titres at the time of challenge.
As expected, none of the pigs vaccinated with the placebo
vaccines had developed antibodies against MRP or EF at the
time of challenge.
Protection
Two weeks after the second vaccination, the pigs were chal-
lenged intravenously in the ear vein with 1 x 107 cfu of the
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Experiment* Antigens
Antibody titre Antibody titre
Adjuvant against MRP Antilog against EF Antilog
MRP WO 13-8a (1.1) 14,263 0O0 0
EF WO 0.0 0 12.88 (1-3) 7131
MRP+EF WO 13.58 (0.9) 11,585 13.3a (0.8) 10,086
MRP+EF+bacterin WO 12.68 (1.7) 6208 13.18 (0.8) 8780
Placebo wo 0-0 0 0-0 0
Placebo No adjuvant 0-0 0 0-0 0
2 MRP+EF WO 14.5b (1t3) 23,170 13.7b (1-8) 13,308
MRP+EF AH 8.6C (1.3) 388 10.6c (1.5) 1552
Bacterin wo 7-3b (1.6) 158 0-0 0
Bacterin AH 0.0 0 0-0 0
Placebo wo 0.0 0 0-0 0
Placebo AH 0.0 0 0-0 0
* In experiment 1, pigs were challenged with the homologous S suis serotype 2 strain 4005
(MRP+EF+), and in experiment 2 with the heterologous S suis serotype 2 strain 3881 (MRP+EF+)
a Significantly different from group placebo/wo, experiment 1
b Significantly different from group placebo/wo, experiment 2
c Significantly different from group placebo/AH, experiment 2
wo Water-in-oil emulsion, AH Aluminium hydroxide-based adjuvant
homologous S suis serotype 2 strain 4005 (experiment 1) or
the heterologous S suis serotype 2 strain 3881 (experiment 2).
Seventeen of the 19 pigs vaccinated with the placebo vaccines
died one to four days after the challenge as a result of the infec-
tion or had to be killed for animal welfare reasons (Table 2).
In these groups, specific clinical signs of disease, such as lame-
ness and nervous signs, were frequently recorded. Non-spe-
cific clinical signs of disease, such as depression, recumbency
and lack of appetite were also frequently observed. The pigs'
body temperatures and leucocyte counts were also increased.
In contrast, the wo-formulated vaccines containing both MRP
and EF conferred a high degree of protection. Compared with
the placebo-vaccinated pigs, mortality was significantly
(P<0.05) lower, and 11 of the 13 pigs survived the challenge,
both with the homologous and with the heterologous serotype
2 strain. The clinical signs of disease and the increase in body
temperatures were also significantly (P<0.05) reduced.
Vaccines containing either MRP or EF were less protective than
the vaccine containing both proteins (Table 2, experiment 1),
and most of the pigs in these groups did not survive the chal-
lenge. However, compared with the pigs in the placebo-vac-
cinated groups, the pigs vaccinated with either MRP or EF
showed significantly (P<0.05) fewer specific clinical signs of
disease and had lower fever and lower leucocyte counts. The
MRP+EF/AH vaccine conferred a low degree of protection; only
three of the five pigs survived the challenge with the heterol-
ogous S suis type 2 strain, but, compared with the placebo-vac-
cinated pigs, the specific clinical signs of disease and the fever
were significantly (P<0.05) lower (Table 2, experiment 2).
Eight of the nine pigs vaccinated with wo-formulated vaccines
containing bacterin were protected against a challenge with
the homologous or heterologous serotype 2 strain; mortality
in these groups was significantly (P<0 05) lower than in the
placebo-vaccinated groups, and there were fewer specific or
non-specific signs of disease (P<0.05) and a lower level of
fever. In contrast, a bacterin/AH vaccine conferred less protec-
tion; four of the five pigs vaccinated with this vaccine died two
to four days after challenge, and specific signs of disease were
observed as often as in the placebo-vaccinated pigs.
Postmortem results confirmed the clinical findings.
Histological examination revealed meningitis, polyserositis
and arthritis in all 19 of the placebo-vaccinated pigs, in four
of the five pigs vaccinated with bacterin/AH, and in three of
the five vaccinated with EF/WO (Table 3). In contrast, the pigs
vaccinated with MRP+EF/WO, bacterin/wo and MRP+EF+bac-
terin/wo had significantly (P<0.05) fewer lesions, and
bacteria were isolated from the lesion sites less frequently.
Lesions were observed at the injection site in the pigs of all
groups, except for those vaccinated with the AH-formulated
placebo vaccine. They ranged in severity from being less than
1 cm3 in size and involving connective tissue only, to being
more than 1 cm3, with necrosis, microabscesses or granulo-
mas (Table 3).
Mortality$ Clinical signs
Number Number Mean number of of disease (%)v Fever Leucocytosis
Experiment* Antigenst Adjuvant of pigs of pigs days after challenge§ Specific# Non-specific* index (%)¶ index (%)A
1 MRP WO 4 3 5.0 15a 21 a 38a 65
EF WO 4 3 2-6 38a 43 65 28
MRP+EF WO 4 1 3 16a 11a1g 31
MRP+EF+bacterin WO 4 1 2 13a 17a 16a 25
Placebo wo 5 5 2 60 70 75 80
Placebo No adjuvant 5 5 2-4 46 84 77 100
2 MRP+EF WO 5 ob NA 1 b 4b 7b 28b
MRP+EF AH 5 2 3.5 13C 31 36C 65
Bacterin wo 5 ob A ob 3b b
Bacterin AH 5 4 2-8 37 56 86 90
Placebo wo 4 3 3.3 31 54 76 88
Placebo AH 5 4 3.3 34 57 78 90
* In experiment 1, pigs were challenged with the homologous S suis serotype 2 strain 4005 (MRP+EF+), and in experiment 2 with the
heterologous S suis serotype 2 strain 3881 (MRP+EF+)
t MRP and EF were purified from S suis serotype 2 strain 4005 (MRP+EF+). Bacterin was prepared from S suis serotype 2 strain 4005
(MRP+EF+)
* Number of pigs that died owing to infection or had to be killed for animal welfare reasons
§ Mean number of days after challenge on which the pigs died owing to infection or had to be killed for animal welfare reasons
v Individual mean percentages were calculated as the number of observations/number of all observations per animal. Group means were
then calculated by total of individual means/number of pigs per group
# Nervous signs and/or lameness on at least one joint
* Inappetence and/or depression
1 Percentage of observations of pigs with a body temperature above 40CA Percentage of observations of pigs in which the concentration of granulocytes was greater than 1010/litre
a Significantly different from group placebo/wo, experiment 1
bSignificantly different from group placebo/wo, experiment 2
c Significantly different fromgroup placebo/AH, experiment 2
NA Not applicable, wo Water-in-oil emulsion, AH Aluminium hydroxide-based adjuvant
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Number of pigs
Number Number of pigs with lesions with lesions at
Experiment* Antigens Adjuvant of pigs Meningitist Polyserositist Polyarthritis§ Total* site of injection
1 MRP wO 4 2 0 2 3 2
EF WO 4 3 3 2 3 2
MRP+EF WO 4 1 1 la 2 4
MRP+EF+bacterin wo 4 1 1 1a 1a 2
Placebo wo 5 4 5 5 5 5
Placebo No adjuvant 5 4 4 5 5 2
2 MRP+EF WO 5 0 ob 0 ob 3
MRP+EF AH 5 1 1 1 2 3
Bacterin wo 5 0 ob 0 ob 3
Bacterin AH 5 2 4 2 4 4
Placebo wo 4 3 3 3 4 4
Placebo AH 5 1 5 3 5 0
* In experiment 1, pigs were challenged with the homologous S suis serotype 2 strain 4005 (MRP+EF+), and in experiment 2 with the
heterologous S suis serotype 2 strain 3881 (MRP+EF+)
t Meningitis was characterised by inflammation of cerebrum, cerebellum, pons, mesencephalon and medulla oblongata
t Polyserositis was characterised by inflammation of peri- and epicardium, thoracic pleura and peritoneum
§ Polyarthritis was characterised by inflammation of carpal, tarsal, knee, elbow, shoulder and hip joints
v Total number of pigs with lesions; some pigs developed more than one lesion
a Significantly different from group placebo/wo, experiment 1
b Significantly different from group placebo/wo, experiment 2
wo Water-in-oil emulsion, AH Aluminium hydroxide-based adjuvant
DISCUSSION
These result show that vaccines containing MRP+EF/WO pro-
tected pigs against challenge with either a homologous or het-
erologous S suis serotype 2 strain with the phenotype
MRP+EF+. The MRP+EF/WO vaccine was as protective as a bac-
terin/wo vaccine. All but one of the pigs vaccinated with
MRP+EF/WO survived the challenge and few specific clinical
signs of disease were observed. The MRP/WO or EF/WO vaccines
were much less protective; three of the four vaccinated pigs
died after challenge. However, compared with the placebo-
vaccinated pigs, the pigs vaccinated with MRP/WO or EF/WO
showed significantly fewer clinical signs of disease. These data
are in accordance with the results of Jacobs and others ( 1996)
who described a vaccine which contained most of the extra-
cellular antigens produced by an S suis serotype 2 strain, with
EF being the most abundant protein. However, the vaccine
only partially protected pigs against challenge with a virulent
S suis type 2 strain.
The protection observed with the MRP and/or EF vaccines
was associated with the levels of anti-MRP and anti-EF anti-
bodies. The MRP+EF/WO vaccine induced high antibody titres
and protected pigs effectively against challenge with either
homologous or heterologous S suis serotype 2 strains. On the
other hand, the vaccine with MRP+EF/AH induced lower anti-
body titres and the pigs were less well protected. In contrast, no
association between anti-MRP and anti-EF titres and protection
was observed with the bacterin vaccines. Pigs vaccinated with
bacterin/wo had low antibody titres against MRP and EF but
nevertheless appeared to be completely protected against chal-
lenge. It seems likely that other antigens than MRP and EF are
responsible for this protection, for example capsular antigens,
as has been suggested by Kebede and others (1990).
wo adjuvant was superior to AH adjuvant in its capacity
to stimulate an immune response after vaccination with MRP
and EF and to confer protection against challenge with viru-
lent S suis serotype 2 strains. Similarly, Ripley (1983) showed
that an oil-based adjuvant produced a significant antibody
response with killed bacterins, whereas only a transient
increase in antibodies was observed after vaccination with an
AH-formulated vaccine. However, it appeared that both wo
and AH adjuvants caused serious lesions at the injection sites,
and a suitable alternative adjuvant or a refinement of wo is
therefore desirable.
Holt and others (1990) found that a vaccine containing
bacterin without an adjuvant protected as well as bacterin for-
mulated either with Freund's incomplete adjuvant or with
aluminium hydroxide gel as an adjuvant. However, the same
experiments showed that the protective response to bacterin
was stimulated when the size of the inoculum was increased
from 1010 to 1011 killed organisms. In this study, the bacterin
contained only 109 killed cells, and a strong potentiating
adjuvant like wo seemed to be necessary to obtain protection.
Whole-cell vaccines are probably serotype-specific,
because protection was achieved only against a strain of a
homologous serotype, and the vaccines failed to protect
against other serotypes (Kebede and others 1990, Foster and
others 1994). Subunit vaccines based on proteins conserved
among serotypes may be more useful in veterinary practice
if they protect against challenge with strains of heterologous
serotypes. Jacobs and others ( 1996) suggested that suilysin, a
thiol-activated haemolysin from S suis serotype 2, could be
such a cross-protection factor. Vaccination challenge experi-
ments in pigs indicated that this vaccine protected against
challenge with a homologous serotype. However, the
haemolysin is absent from quite a number of strains of S suis
isolated from diseased pigs in the field. This implies that other
vaccine components will be necessary to provide protection
against all field strains (Jacobs and others 1996, Segers and
others 1998). A 52 kDa immunoglobulin-binding protein
which has recently been shown to be identical to a 60 kDa
heat-shock protein that is produced by various serotypes,
could be another candidate for a subunit vaccine (Serhir
and others 1993, Benkirane and others 1997, 1998). The
protective value of this protein has not been tested.
In Europe, the USA and Australia, most of the S suis
serotype 2 strains isolated from diseased pigs produce MRP
and EF (Mwaniki and others 1994, Galina and others 1996,
Wisselink and others 2000). In these countries an MRP+EF vac-
cine could therefore be of great value. However, most of the
S suis serotype 2 strains isolated from diseased pigs in Canada
appeared to be MRP and EF negative (Gottschalk and others
1998). Apparently, Canadian strains differ from strains iso-
lated in other countries. The proteins MRP and/or EF are not
only produced by serotype 2 strains. High percentages of
European S suis serotype 1, 1/2 and 14 strains, isolated from
tissues associated with S suis infections such as brain, serosa,
joint, heart and other organs of diseased pigs, expressed MRP
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and EF, and more than 80 per cent of the S suis serotype 9
strains produced an MRP+ protein, a high molecular weight
variant of the 136 kDa MRP (Wisselink and others 2000). In
addition to serotype 2 strains, strains of serotypes 1, 1/2, 7, 9
and 14 are frequently isolated from diseased pigs. Further
work is needed to determine whether MRP and EF are involved
in the protection of pigs infected with strains of other
serotypes producing MRP and/or EF.
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